AI Automated Translation.

Font Size

Share

Ceres to Collaborate with UAE Medical Investment Group on "Smart Ward and Cardiac Diagnostic Center Development"

Ceres to Collaborate with UAE Medical Investment Group on "Smart Ward and Cardiac Diagnostic Center Development"

Lee Young-shin, CEO of Ceres (right), and Muhammed Shihabuddin, Chief Financial Officer (CFO) of VPS Healthcare, pose for a photo at the signing ceremony for a Memorandum of Understanding (MOU) on "Establishing Smart Wards and Setting Up an Arrhythmia Center," held on the 3rd at DoubleTree by Hilton Seoul Pangyo. /Photo provided by Ceres
Lee Young-shin, CEO of Ceres (right), and Muhammed Shihabuddin, Chief Financial Officer (CFO) of VPS Healthcare, pose for a photo at the signing ceremony for a Memorandum of Understanding (MOU) on "Establishing Smart Wards and Setting Up an Arrhythmia Center," held on the 3rd at DoubleTree by Hilton Seoul Pangyo. /Photo provided by Ceres

Ceres announced on the 16th that it has signed a Memorandum of Understanding (MOU) with VPS Healthcare Holdings (hereinafter referred to as VPS), a major medical investment group in the United Arab Emirates (UAE), to develop AI-powered smart wards and cardiac diagnostic centers. Through this agreement, Ceres will pursue the supply of its bed monitoring platform "thynC" and AI arrhythmia diagnostic solution "mobiCARE" to VPS's medical network.

This collaboration involves jointly establishing thynC-based AI smart wards and mobiCARE-based cardiac diagnostic centers at major private hospitals in the UAE.

VPS is the largest shareholder, holding a 70% stake in Burjeel Holdings, a medical group listed on the Abu Dhabi Securities Exchange (ADX). Burjeel Holdings operates major hospital brands in the Middle East region, including Burjeel, Medeor, LKorea Land and Housing Corporation, and Lifecare. As of the end of June this year, it possessed a total of 94 medical facilities, including 20 hospitals and 44 medical centers. Last year's revenue was 5.5 billion dirhams (approximately 1.9 trillion won). In addition to Burjeel Holdings, VPS holds medical-related investment assets in India and other regions, making it possible to expect an expansion of the scope of future cooperation.

Based on clinical operational experience accumulated at domestic tertiary general hospitals, Ceres will apply integrated AI diagnostic and monitoring services to VPS's medical network. The company's strategy is to expand the mobiCARE business in the public healthcare sector, which was previously pursued centered around PureHealth, the UAE's largest healthcare group, to large-scale private hospitals such as Burjeel Holdings, thereby fully commercializing its operations in the Gulf Cooperation Council (GCC) region, including the UAE.

For this agreement, key officials from VPS, including Muhammed Shihabuddin, Chief Financial Officer (CFO), and Shijoth Vijayan, Project Director, visited Korea. VPS representatives visited Samsung Seoul Hospital on the 6th to experience smart wards incorporating various digital healthcare technologies, including thynC.

The AI smart ward that Ceres and VPS will develop is a project to manage patients' vital signs, such as electrocardiograms, oxygen saturation, and body temperature, in real time using thynC, and to establish a smart ward model suitable for the UAE medical environment. The arrhythmia diagnostic center aims to enhance the early diagnosis capabilities of local medical institutions by establishing a system for long-term electrocardiogram testing and AI analysis and interpretation based on mobiCARE.

Through this, Ceres will pursue an integrated healthcare service model linking inpatient monitoring with outpatient electrocardiogram diagnostics. The company also plans to collaborate with VPS in the fields of remote patient monitoring and joint research and clinical validation of medical AI.

Ceres is focusing on entering global markets this year. In May, it signed a contract to supply mobiCARE worth at least 22 billion won over three years to ONE HEALTH, a subsidiary of UAE's PureHealth. Following this, in June, it obtained product approval for mobiCARE from the U.S. Food and Drug Administration (FDA).

Lee Young-shin, CEO of Ceres, stated, "This collaboration is an important opportunity to expand Ceres' AI diagnostic and monitoring technology, operated at domestic tertiary general hospitals, to large-scale private medical networks in the Middle East." He added, "We will concretize the development of thynC-based smart wards and mobiCARE-based cardiac diagnostic centers with VPS and connect them to tangible business results in the UAE market."

"This article was translated using AI and may differ slightly from the original."